

Makena® Prescription Form

STEP 1 Complete Patient & Insurance Information

→ Patient or Legal Guardian Signature:

Relationship to Patient:

First Name	Last Name	MI
Address		
City	State	ZIP
Home Phone #		Work Phone #
Cell Phone #	Best Time to Contact ☐ Morning ☐ Day ☐ Evening	Email
Date of Birth		Primary Language if Not English:
Medicaid ID#		
Step 2 Read ar	nd Sign Voluntary Patient Authorizations	
I. For purposes of the	se Authorizations:	
"AMAG" means AMAG "PHI" means personal insurance, as well as a be specifically identifial	Pharmaceuticals, Inc., and its affiliates, subsidiaries, representatives, health information, including, but not limited to, information relating to il information provided on this form and any prescription or by you dir ole to you or your baby. For example: AMAG may publish a report that si e information would not be traceable to you.	your medical condition, treatment, care management, and healti rectly; and " De-Identified Data " means information that will no
protections by law, such	t, payment, enrollment, or eligibility for benefits ("Access") is not condir n as HIPAA. Unlike your healthcare provider, however, AMAG is not "cov . AMAG agrees to only use your PHI as you authorize below, and to not	vered" by HIPAA, which means that any PHI disclosed to AMAG is
expires five (5) years for c/o AllCare Plus Pharm	Cancellation Rights: You are entitled to a copy of each Authorizatio rom the date signed below. You may cancel any Authorization at any acy, 50 Bearfoot Rd., Northborough, MA 01532, or by phone by calling through the Authorization.	time by mailing a letter requesting such cancellation to AMAC
following purposes: (1) healthcare providers an product registration pro and (b) ask me to partic disclosed under this Au	By signing this Authorization, I authorize my health plans, healthcare to assist with my obtaining and being treated with Makena, such as to: not about my medical care; (c) help third parties provide care-relagram required for my treatment; (2) to contact me during and after my inpate in patient programs and surveys; and (3) to review and publish D thorization is no longer protected by federal privacy laws; (ii) my pharm be paid for that information; (iii) I may refuse to sign this Authorization is.	(a) establish my eligibility for benefits; (b) communicate with m ated products, supplies, or services; and (d) register me in an treatment to: (a) provide me with treatment or support materials be-Identified Data. Further, I understand and agree that: (i) my Phacy may share my PHI related to the dispensing of Makena, an
→ Patient or Legal Gu	ardian Signature:	
Relationship to Patient:		Date:
no cost to me, designed t (1) I am voluntarily choosi and mail to provide the P have Access; and (6) I un	t Authorization: I have provided my PHI Authorization above and wish o help me stay on track with treatment and provide me with educational infor ing to enroll in this Program; (2) AMAG may use my PHI to provide the Progran rogram; (4) AMAG may review and publish De-Identified Data it receives fror derstand my Copy, Expiration, and Cancellation Rights. thorize the physician or the physician employees to accept delivery	rmation. By signing this Authorization, I acknowledge and agree that: n; (3) AMAG may contact me via phone, email, m the Program; (5) I may refuse to sign this Authorization and still

Fax completed form to 919-858-0809 or 866-902-5755

Fax completed form directly to the pharmacists at Triangle Compounding Pharmacy at: 919-858-5145 OR 866-902-5755 Call the pharmacy about rush orders at: 919-858-0809 OR 866-858-0809

lo your nationt prognant with a singl	atan and have a history of singlets	on anantanagua protorn	a hirth (27 w	noka of gostation)? Plagas and full proparibi
is your patient pregnant with a singli information. \square Yes $\ \square$ No	eton and have a history of singleto	on spontaneous pretern	n birun (<37 W	eeks of gestation)? Please see full prescribi
Current Gestational Age: we sthe patient currently receiving Mal	-	recorded:		
CD-10 Code: □ 009.212 Supervision of pregnanc □ 009.213 Supervision of pregnanc □ 009.219 Supervision of pregnanc □ 00ther:	y with history of preterm labor, thin	rd trimester		Note: The ICD-10 codes start with an uppercase "0" which is followed by a zero.
STEP 4 Prescriber Inform	nation			
Prescriber's Name (Last, First)				
Address	City		State	ZIP
Practice Name	Office Phone #		Office Fax #	
NPI #			Medicaid Pr	ovider #
Office Contact(s)	Direct Phone #		e #	
After-hours Phone #			Email	
	□ Phone □ Fax □ Email		Email	
Preferred Method of Communication		wn as J1725 or Q9		
Preferred Method of Communication STEP 5 Complete Makena	a Rx (J1726, previously kno		986)	ion
Preferred Method of Communication STEP 5 Complete Makena Subcutaneous Auto-Inject Rx: Makena (hydroxyprogesterone 275 mg/1.1 mL (250 mg/mL)	a Rx (J1726, previously kno tor -OR- e caproate injection)	- Intramusc Rx: Makena (l	986) ular Injecti hydroxyproge	i on sterone caproate injection) 250 mg/mL L single-dose vials
Preferred Method of Communication STEP 5 Complete Makena Subcutaneous Auto-Inject Rx: Makena (hydroxyprogesterone 275 mg/1.1 mL (250 mg/mL) Dispense quantity 4 x 1 single-do auto-injectors (64011-301-03) X (ie, through 36 weeks) or delivery Sig: Inject 1.1 mL subcutaneously via (every 7 days)	a Rx (J1726, previously kno tor -OR- e caproate injection) se, pre-filled subcutaneous refills until 37 weeks y, whichever comes first	- Intramusc Rx: Makena (I □ Dispense qu (64011-247 or delivery, Sig: Inject 1 m □ 18-g needle	986) ular Injecti hydroxyproge uantity 4 x 1 m (-02) X whichever com L IM each wee e & 3 mL syring	sterone caproate injection) 250 mg/mL L single-dose vials refills until 37 weeks (ie, through 36°weeks
Preferred Method of Communication STEP 5 Complete Makena Subcutaneous Auto-Inject Rx: Makena (hydroxyprogesterone 275 mg/1.1 mL (250 mg/mL) Dispense quantity 4 x 1 single-do auto-injectors (64011-301-03) X. (ie, through 36 weeks) or delivery Sig: Inject 1.1 mL subcutaneously via every 7 days) Preferred Injection Setting: Healthcare provider office	a Rx (J1726, previously kno tor -OR- e caproate injection) se, pre-filled subcutaneous refills until 37 weeks y, whichever comes first auto-injector each week	- Intramusc Rx: Makena (I □ Dispense qu (64011-247 or delivery, Sig: Inject 1 m □ 18-g needle □ 21-g, 1½" r	986) ular Injecti hydroxyproge uantity 4 x 1 m r-02) X whichever com L IM each wee 8 & 3 mL syring needle	sterone caproate injection) 250 mg/mL L single-dose vials refills until 37 weeks (ie, through 365weeks ess first k (every 7 days) pe # X refills # X refills
Preferred Method of Communication STEP 5 Complete Makena Subcutaneous Auto-Inject Rx: Makena (hydroxyprogesterone 275 mg/1.1 mL (250 mg/mL) Dispense quantity 4 x 1 single-do auto-injectors (64011-301-03) X. (ie, through 36 weeks) or delivery Sig: Inject 1.1 mL subcutaneously via (every 7 days) Preferred Injection Setting: Healthcare provider office Home healthcare administration by	a Rx (J1726, previously knotor -OR- e caproate injection) se, pre-filled subcutaneous refills until 37 weeks y, whichever comes first auto-injector each week	- Intramusc Rx: Makena (I □ Dispense qu (64011-247 or delivery, Sig: Inject 1 m □ 18-g needle □ 21-g, 1½" r	986) ular Injecti hydroxyproge uantity 4 x 1 m r-02) X whichever com L IM each wee 8 & 3 mL syring needle	sterone caproate injection) 250 mg/mL L single-dose vials refills until 37 weeks (ie, through 365weeks ess first k (every 7 days) pe # X refills # X refills
Preferred Method of Communication STEP 5 Complete Makena Subcutaneous Auto-Inject Rx: Makena (hydroxyprogesterone 275 mg/1.1 mL (250 mg/mL) Dispense quantity 4 x 1 single-do auto-injectors (64011-301-03) X (ie, through 36 weeks) or delivery Sig: Inject 1.1 mL subcutaneously via (every 7 days) Preferred Injection Setting: Healthcare provider office Home healthcare administration b Other:	a Rx (J1726, previously knotor -OR- e caproate injection) se, pre-filled subcutaneous refills until 37 weeks y, whichever comes first auto-injector each week by Optum® home nursing services of	- Intramusc Rx: Makena (I □ Dispense qu (64011-247 or delivery, Sig: Inject 1 m □ 18-g needle □ 21-g, 1½" r	986) ular Injecti hydroxyproge uantity 4 x 1 m (-02) X whichever com L IM each wee e & 3 mL syring needle nd injection), if	sterone caproate injection) 250 mg/mL L single-dose vials refills until 37 weeks (ie, through 36°weeks les first k (every 7 days) le # X refills # X refills approved by insurance
	a Rx (J1726, previously knotor -OR- e caproate injection) se, pre-filled subcutaneous refills until 37 weeks y, whichever comes first auto-injector each week by Optum® home nursing services of	- Intramusc Rx: Makena (I □ Dispense qu (64011-247 or delivery, Sig: Inject 1 m □ 18-g needle □ 21-g, 1½" r	986) ular Injecti hydroxyproge uantity 4 x 1 m (-02) X whichever com L IM each wee e & 3 mL syring needle nd injection), if	sterone caproate injection) 250 mg/mL L single-dose vials refills until 37 weeks (ie, through 365weeks ess first k (every 7 days) pe # X refills # X refills

I authorize AMAG Pharmaceuticals, Inc., and its affiliates, agents and contractors ("AMAG") to be my designated agent to (1) provide any information on this form to the Makena Care Connection for use as authorized by the above named patient (2) provide any information on this form to the insurer of the above named patient and (3) forward the above prescription by fax or by other mode of delivery to a pharmacy that can provide the prescribed medication for the above named patient. If my patient has not signed the Patient Authorization section of this form, I certify that I have my patient's HIPAA authorization for the release of my patient's identification and insurance information to AMAG for benefits verification and coordination of benefits.

I certify that this therapy is medically necessary and that this information is accurate to the best of my knowledge.

→ Prescriber's Signature:	Date:
Dispense As Written/Do Not Substitute:	Date: